ClinicalTrials.gg
CompletedNCT00916383DTP-SystemUpdated Oct 28, 2021Results posted

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

A Phase 2 interventional study of 350 mg Donepezil Transdermal Patch and Placebo Patch in Irritation/Irritant, sponsored by Teikoku Pharma USA, Inc.. Completed at 7 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Teikoku Pharma USA, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This study is designed to assess skin tolerability, skin irritation, and adhesion of the 350 mg Donepezil Transdermal Patch (DTP-system), following 3, 7-day applications to 3 specific areas of the body (upper back, upper middle arm, side of torso) of elderly Alzheimer's patients. The total application time for the DTP-system is 21 days.

Read the detailed description

This is a randomized, placebo-controlled study designed to evaluate skin irritation, skin tolerability, and adhesion of the 350 mg DTP-system following 3 consecutive 7-day applications to 3 specific areas of the body (upper back, upper arm, side of torso) of elderly Alzheimer's patients. The total exposure time for the DTP-system is 21 days.

All patients receive 1 Donepezil Transdermal Patch (DTP-system) and 1 placebo patch, each applied to opposite sides of the body (e.g., placebo patch to the left side of the upper back, and DTP-system to the right side of the upper back). Patients are randomized to receive the active patch to either the left or the right side of the body according to 1 of 6 treatment sequences listed below. The treatment sequence is repeated for the opposite side of the body for a total of 12 treatment sequences (4 patients in each treatment sequence). The patches are applied to one of 3 body locations for 7 days, for a total exposure period of 21 days, according to one of the following sequences:

  1. Upper Back, Upper Arm, Side of Torso (Right)
  2. Upper Arm, Side of Torso, Upper Back (Right)
  3. Side of Torso, Upper Back, Upper Arm (Right)
  4. Upper Back, Side of Torso, Upper Arm (Right)
  5. Upper Arm, Upper Back, Side of Torso (Right)
  6. Side of Torso, Upper Arm, Upper Back (Right)
  7. Upper Back, Upper Arm, Side of Torso (Left)
  8. Upper Arm, Side of Torso, Upper Back (Left)
  9. Side of Torso, Upper Back, Upper Arm (Left)
  10. Upper Back, Side of Torso, Upper Arm (Left)
  11. Upper Arm, Upper Back, Side of Torso (Left)
  12. Side of Torso, Upper Arm, Upper Back (Left)

Patches are applied on Days 1, 8, and 15 according to the randomization schedule. Oral Aricept is taken daily through Day -1, and is re-started on Day 22 or at the time of early termination if before Day 22. Patients are seen in the clinic at Screening and on Days 1, 8, 15, 22, and at the End of Study Visit; for all other daily visits, the patients may be seen either at the clinic or in their residence, provided the assessments are completed as described in the protocol. Skin irritation is assessed immediately upon patch removal and at 1, 24, and 48 hours after removal.

02

Conditions studied

  • Irritation/Irritant

Keywords

  • Skin Irritation
  • Donepezil Transdermal Patch System
  • Elderly
  • Alzheimer's subjects
  • Skin Irritation in elderly Alzheimer's subjects
03

In context

Lead sponsor

Teikoku Pharma USA, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 65 years of age.
  • Established dose of Aricept 10 mg at least 2 months prior to enrollment.
  • Established diagnosis of stable Alzheimer's disease treated with oral Aricept
  • Must be willing to change from oral Aricept to DTP (and placebo patch).
  • of at least 18 and a minimum weight of at least 45 kg.
  • Blood pressure (sitting) must be diastolic \<95mmHg, and systolic \<145, stable for at least 3 months. Patients with well-controlled hypertension (with medication) may enroll as long as 3-month stability criterion is met.
  • Those with stable cardiac disease may be enrolled provided the patient has been on appropriate medication for 3 months prior to screening. Those with a pacemaker may be enrolled.
  • Pulse rate between 45 - 100 bpm; respirations between 8 - 20 per minute.
  • Those with thyroid disease may enroll if stable on treatment for at least 3 months prior to screening, and maintain the same dose of thyroid medication throughout the study.
  • Must have a caregiver who is either living with the patient or is in daily contact with the patient, agrees to be present at all visits, provide information as required, and ensure compliance with the medication schedule.
  • Free from any abnormality at Screening which may compromise the patient's ability to participate.
  • Free of any dermatologic conditions, excessive hair or skin allergies and sensitivities.
  • Male patients who have female partners of must use a condom.
  • Must understand and provide written (or have a Legally Authorized Representative who is able), prior to the initiation of any protocol-specific procedures.
  • Must be willing and able to abide by all study requirements and restrictions.
  • Must be on stable medications for at least 30 days prior to enrollment into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of systemic or topical antihistamines within 72 hours prior to enrollment, or systemic or topical within 3 weeks of study enrollment or foreseen use during the study.
  • History of allergy to Donepezil hydrochloride or to piperidine derivatives, related drugs, or any of the drug or other drug product components.
  • Those with a recent (\< 2 years) cancer (except for non-melanoma skin cancers, females with in-situ cancer of the cervix or males with localized prostate cancer requiring no treatment).
  • Presence of history of a psychiatric disorder, or other seizure disorder deemed .
  • Those with a known plan for elective surgery during the study period.
  • Those taking antidepressant medication.
  • Abnormality (e.g., scar, tattoo) or unhealthy skin (e.g., burns, wounds) at the application site; or an existing chronic skin disease or history of skin disease at the application site(s) within the 30 days prior to enrollment.
  • Treatment with any drug within 30 days prior to enrollment in the study.
  • Any condition which would make the patient or caregiver, in the opinion of the investigator or designee, not suitable for the study for any reason.
  • Current or pending legal charges that may affect patient or caregiver compliance.
  • Treatment with medications for use with Aricept
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Upper Back

    350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.

    Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch

  • Experimental
    Upper Arm

    350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.

    Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch

  • Experimental
    Side of Torso

    350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.

    Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch

Interventions

  • Active and placebo patches will be applied to opposite sides for 7 days.

  • DrugPlacebo Patch

    Active and placebo patches will be applied to opposite sides for 7 days.

06

What researchers measure

Primary outcomes

  1. Skin Irritation (Erythema and Edema)

    Erythema and edema were used to determine skin irritation using a modified Draize scale. Score 0 = no erythema/edema; Score 1 = very slight erythema/edema; Score 2 = well-defined erythema/slight edema; Score 3 = moderate to severe erythema/edema; Score 4 = severe erythema/edema.

    Time frame: Immediately after patch removal

  2. Skin Irritation (Erythema)

    Erythema was used to determine skin irritation using a modified Draize scale. Score 0 = no erythema; Score 1 = very slight erythema; Score 2 = well-defined erythema; Score 3 = moderate to severe erythema; Score 4 = severe erythema.

    Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)

  3. Skin Irritation (Edema)

    Edema was used to determine skin irritation using a modified Draize scale. Score 0 = no edema; Score 1 = very slight edema; Score 2 = slight edema; Score 3 = moderate to severe edema; Score 4 = severe edema.

    Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)

  4. Skin Irritation (Papules and Vesicles)

    Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.

    Time frame: Immediately after patch removal

  5. Skin Irritation (Papules and Vesicles)

    Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.

    Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)

  6. Skin Irritation (Other Skin Effects)

    Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.

    Time frame: Immediately after patch removal

  7. Skin Irritation (Other Skin Effects)

    Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.

    Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)

Secondary outcomes

  1. Safety, Tolerability, and Adhesion

    See Adverse Event section for Safety assessment. Adhesion was assessed according to the following scoring criteria: Score 0 = approximately \> 90% adhered (essentially no lift off the skin); Score 1 = approximately 75% to \< 90% adhered (some edges only lifting off the skin); Score 2 = approximately 50% to \< 75% adhered (less than half of the system lifting off the skin); Score of 3 = approximately \< 50% adhered but not detached (more than half of the system lifting off the skin without falling off); Score of 4 = Patch-system detached (patch /overlay completely off the skin).

    Time frame: Safety was assessed throughout the study. Adhesion was assessed daily and immediately prior to patch removal on Days 8, 15, and 22.

07

Results

Posted Apr 22, 2016

Participant flow

The study was conducted at 7 clinical sites during May and June 2009. Patients received 1 placebo patch and 1 Donepezil Transdermal Patch, each applied to opposite sides of the body. The 7-day patches were applied to 1 of 3 consecutive body locations according to 1 of 6 treatment sequences for a total treatment period of 21 days.

Participant flow — Overall Study
MilestoneAll Participants
Started49
Completed46
Not completed3
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Protocol violation1

Outcome measures

PrimarySkin Irritation (Erythema and Edema)

Erythema and edema were used to determine skin irritation using a modified Draize scale. Score 0 = no erythema/edema; Score 1 = very slight erythema/edema; Score 2 = well-defined erythema/slight edema; Score 3 = moderate to severe erythema/edema; Score 4 = severe erythema/edema.

Time frame:
Immediately after patch removal
Reported as:
Mean · units on a scale
Skin Irritation (Erythema and Edema)
units on a scaleUpper BackUpper ArmSide of Torso
Erythema, Placebo0.9 ± 0.850.7 ± 0.761.1 ± 0.89
Erythema, DTP-System1.0 ± 0.750.8 ± 0.751.0 ± 0.85
Edema, Placebo0.6 ± 0.820.6 ± 0.680.7 ± 0.71
Edema, DTP-System0.6 ± 0.760.5 ± 0.680.7 ± 0.73
PrimarySkin Irritation (Erythema)

Erythema was used to determine skin irritation using a modified Draize scale. Score 0 = no erythema; Score 1 = very slight erythema; Score 2 = well-defined erythema; Score 3 = moderate to severe erythema; Score 4 = severe erythema.

Time frame:
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Reported as:
Mean · units on a scale
Skin Irritation (Erythema)
units on a scaleUpper BackUpper ArmSide of Torso
1 hour after patch removal, Placebo0.8 ± 0.880.6 ± 0.650.8 ± 0.82
1 hour after patch removal, DTP-system0.9 ± 0.730.6 ± 0.640.7 ± 0.74
24 hours after patch removal, Placebo0.6 ± 0.800.3 ± 0.520.7 ± 0.71
24 hours after patch removal, DTP-system0.4 ± 0.620.4 ± 0.570.4 ± 0.62
48 hours after patch removal, Placebo0.3 ± 0.540.2 ± 0.460.4 ± 0.65
48 hours after patch removal, DTP-system0.2 ± 0.430.2 ± 0.430.3 ± 0.59
PrimarySkin Irritation (Edema)

Edema was used to determine skin irritation using a modified Draize scale. Score 0 = no edema; Score 1 = very slight edema; Score 2 = slight edema; Score 3 = moderate to severe edema; Score 4 = severe edema.

Time frame:
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Reported as:
Mean · units on a scale
Skin Irritation (Edema)
units on a scaleUpper BackUpper ArmSide of Torso
1 hour after patch removal, Placebo0.6 ± 0.760.6 ± 0.680.6 ± 0.71
1 hour after patch removal, DTP-system0.6 ± 0.730.4 ± 0.570.6 ± 0.71
24 hours after patch removal, Placebo0.1 ± 0.410.2 ± 0.380.2 ± 0.47
24 hours after patch removal, DTP-system0.1 ± 0.330.1 ± 0.340.1 ± 0.40
48 hours after patch removal, Placebo0.0 ± 0.140.0 ± 0.150.1 ± 0.25
48 hours after patch removal, DTP-system0.0 ± 0.140.0 ± 0.150.0 ± 0.29
PrimarySkin Irritation (Papules and Vesicles)

Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.

Time frame:
Immediately after patch removal
Reported as:
Number · participants
Skin Irritation (Papules and Vesicles)
participantsUpper BackUpper ArmSide of Torso
Placebo, Score >1955
DTP-System, Score >1722
Placebo, Score >2211
DTP-System, Score >2100
PrimarySkin Irritation (Papules and Vesicles)

Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.

Time frame:
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Reported as:
Number · participants
Skin Irritation (Papules and Vesicles)
participantsUpper BackUpper ArmSide of Torso
1 hour after patch removal, Placebo, Score >1965
1 hour after patch removal, DTP-System, Score >1722
1 hour after patch removal, Placebo, Score >2211
1 hour after patch removal, DTP-System, Score >2100
24 hours after patch removal, Placebo, Score >1544
24 hours after patch removal, DTP-System, Score >1522
24 hours after patch removal, Placebo, Score >2211
24 hours after patch removal, DTP-System, Score >2000
48 hours after patch removal, Placebo, Score >1523
48 hours after patch removal, DTP-System, Score >1511
48 hours after patch removal, Placebo, Score >2211
48 hours after patch removal, DTP-System, Score >2000
PrimarySkin Irritation (Other Skin Effects)

Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.

Time frame:
Immediately after patch removal
Reported as:
Number · participants
Skin Irritation (Other Skin Effects)
participantsUpper BackUpper ArmSide of Torso
Placebo, Score ≥11098
DTP-System, Score ≥1878
Placebo, Score =6260
DTP-System, Score =6242
PrimarySkin Irritation (Other Skin Effects)

Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.

Time frame:
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Reported as:
Number · participants
Skin Irritation (Other Skin Effects)
participantsUpper BackUpper ArmSide of Torso
1 hour after patch removal, Placebo, Score ≥11098
1 hour after patch removal, DTP-System, Score ≥1978
1 hour after patch removal, Placebo, Score =6260
1 hour after patch removal, DTP-System, Score =6342
24 hours after patch removal, Placebo, Score ≥1373
24 hours after patch removal, DTP-System, Score ≥1363
24 hours after patch removal, Placebo, Score =6251
24 hours after patch removal, DTP-System, Score =6232
48 hours after patch removal, Placebo, Score ≥1261
48 hours after patch removal, DTP-System, Score ≥1252
48 hours after patch removal, Placebo, Score =6251
48 hours after patch removal, DTP-System, Score =6232
SecondarySafety, Tolerability, and Adhesion

See Adverse Event section for Safety assessment. Adhesion was assessed according to the following scoring criteria: Score 0 = approximately \> 90% adhered (essentially no lift off the skin); Score 1 = approximately 75% to \< 90% adhered (some edges only lifting off the skin); Score 2 = approximately 50% to \< 75% adhered (less than half of the system lifting off the skin); Score of 3 = approximately \< 50% adhered but not detached (more than half of the system lifting off the skin without falling off); Score of 4 = Patch-system detached (patch /overlay completely off the skin).

Time frame:
Safety was assessed throughout the study. Adhesion was assessed daily and immediately prior to patch removal on Days 8, 15, and 22.
Reported as:
Number · percentage of patients with scores <2
Safety, Tolerability, and Adhesion
percentage of patients with scores <2Upper BackUpper ArmSide of Torso
Placebo - Worst adhesion score over 7 days89.693.893.8
DTP system - Worst adhesion score over 7 days83.489.385.4
Placebo - Day 197.9100100
DTP system - Day 195.897.9100
Placebo - Day 2100100100
DTP system - Day 297.897.897.9
Placebo - Day 310097.9100
DTP system - Day 395.710095.8
Placebo - Day 410095.8100
DTP system - Day 495.697.797.8
Placebo - Day 597.9100100
DTP system - Day 593.210093.3
Placebo - Day 693.597.897.9
DTP system - Day 695.495.495.5
Placebo - Day 791.397.895.8
DTP system - Day 793.197.693.0

Adverse events

Collected over Adverse event data were collected from the time the patient signed the Informed Consent Form until study discharge (Day 24) (3 days after removal of the last patch).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Systemic Events—1/49 (2%)3/49 (6.1%)
DTP-system—0/49 (0%)14/49 (28.6%)
Placebo Patch—0/49 (0%)15/49 (30.6%)
Most frequent serious events
Most frequent serious events
EventSystemic EventsDTP-systemPlacebo Patch
CoughRespiratory, thoracic and mediastinal disorders1/490/490/49
Increased upper airway secretionRespiratory, thoracic and mediastinal disorders1/490/490/49
DyspnoeaRespiratory, thoracic and mediastinal disorders1/490/490/49
Most frequent other events
Most frequent other events
EventSystemic EventsDTP-systemPlacebo Patch
Application site pruritusGeneral disorders0/4914/4915/49
Confusional StatePsychiatric disorders3/490/490/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
All Participants79.5 ± 6.47
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female29
Male20
08

Study locations

7 sites
  • Xenoscience, Inc
    Phoenix, Arizona 85004, United States
  • Margolin Brain Institute
    Fresno, California 93720, United States
  • Collaborative Neuroscience Network, Inc
    Garden Grove, California 92845, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Apex Research Institute
    Santa Ana, California 92705, United States
  • Meridien Research
    Brooksville, Florida 34613, United States
  • Miami Jewish Home and Hospital for the Aged
    Miami, Florida 33137, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2009
First posted
Jun 9, 2009
Start
May 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Apr 22, 2016
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00916383
Lead sponsor
Teikoku Pharma USA, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2009
Start date
May 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Apr 22, 2016
Last update
Oct 28, 2021

Study contacts

James Song, MS, MBA
study director · Teikoku Pharma USA, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion